Loading…
Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial
Purpose To evaluate laser combined with intravitreal triamcinolone acetonide (IVTA) for the management of patients with proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME). Design Randomized clinical trial. Methods settings: Single center. study population: Twent...
Saved in:
Published in: | American journal of ophthalmology 2009-02, Vol.147 (2), p.291-297.e2 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3 |
---|---|
cites | cdi_FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3 |
container_end_page | 297.e2 |
container_issue | 2 |
container_start_page | 291 |
container_title | American journal of ophthalmology |
container_volume | 147 |
creator | Maia, Otacilio O Takahashi, Beatriz S Costa, Rogerio A Scott, Ingrid U Takahashi, Walter Y |
description | Purpose To evaluate laser combined with intravitreal triamcinolone acetonide (IVTA) for the management of patients with proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME). Design Randomized clinical trial. Methods settings: Single center. study population: Twenty-two patients with bilateral treatment-naïve moderate PDR and CSME. intervention: Laser (panretinal and macular) photocoagulation was performed in each eye, followed by IVTA in one randomly assigned eye. Best-corrected visual acuity (BCVA), fundus photography, and optical coherence tomography were performed at baseline and at months 1, 3, 6, 9, and 12. main outcome measures: Changes in BCVA, central macular thickness (CMT), and total macular volume (TMV). Results The mean logarithm of the minimal angle of resolution (logMAR) BCVA improved significantly, and mean CMT and TMV were significantly reduced in the IVTA group compared with the laser-only group (controls) at all study follow-up visits ( P < .001). The mean logMAR BCVA (Snellen equivalent) was 0.44 (20/50−2 ) for the IVTA group and 0.38 (20/50+1 ) for the controls at baseline, and 0.12 (20/25−1 ) for the IVTA group and 0.32 (20/40−1 ) for the controls at 12 months ( P < .001). The mean CMT and TMV were, respectively, 360 μm and 8.59 mm 3 for the IVTA group and 331 μm and 8.44 mm 3 for the controls at baseline, and 236 μm and 7.32 mm 3 for the IVTA group and 266 μm and 7.78 mm 3 for the controls at 12 months ( P < .001). Conclusions The combination of laser photocoagulation with IVTA was associated with improved BCVA and decreased CMT and TMV when compared with laser photocoagulation alone for the treatment of moderate PDR with CSME. |
doi_str_mv | 10.1016/j.ajo.2008.08.024 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66847761</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002939408006673</els_id><sourcerecordid>66847761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3</originalsourceid><addsrcrecordid>eNp9kt2K1DAUx4so7uzqA3gjAdG7jkmbSRoFQcZVF0ZWxvU6nKanmLFNxqQdmH0RX9fUKS7shXBIcsjvfOT8k2XPGF0yysTr3RJ2fllQWi0nK_iDbMEqqXJWKfYwW1BKi1yVip9l5zHukiskl4-zs3RfqHJVLLLfa9_X1mFDNhAxEHANuXJDgIMdAkJHboKF3ljnO--QtD6Qr8F3tsUAgz0g-WChxsEask2r83sYfhz_ZvkCZuwgkMsGe3hDrh3mR0z-FuPYDZH4lgDZJtL39jbVX3fWWTNX7J5kj1roIj6d94vs-8fLm_XnfHP96Wr9fpMbLviQoyxNY-qylWWhTG2gLmqkrF3Jkjd8Rat0ZqyBVq0kGCbpynCujJJKpEDalhfZq1PeffC_RoyD7m002HXg0I9RC1FxKQVL4It74M6PwaXeNGNlVQnGFU0UO1Em-BgDtnofbA_hqBnVk2Z6p5NmetJMT1bwFPN8zjzWPTZ3EbNICXg5AxDTgNoAztj4jysY45XgE_f2xGEa2MFi0NFYdAYbG9AMuvH2v228uxdtZkV-4hHj3Wt1LDTV36bPNf2tNGMqhCzLP0Z8ylY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1138861490</pqid></control><display><type>article</type><title>Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial</title><source>ScienceDirect Journals</source><creator>Maia, Otacilio O ; Takahashi, Beatriz S ; Costa, Rogerio A ; Scott, Ingrid U ; Takahashi, Walter Y</creator><creatorcontrib>Maia, Otacilio O ; Takahashi, Beatriz S ; Costa, Rogerio A ; Scott, Ingrid U ; Takahashi, Walter Y</creatorcontrib><description>Purpose To evaluate laser combined with intravitreal triamcinolone acetonide (IVTA) for the management of patients with proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME). Design Randomized clinical trial. Methods settings: Single center. study population: Twenty-two patients with bilateral treatment-naïve moderate PDR and CSME. intervention: Laser (panretinal and macular) photocoagulation was performed in each eye, followed by IVTA in one randomly assigned eye. Best-corrected visual acuity (BCVA), fundus photography, and optical coherence tomography were performed at baseline and at months 1, 3, 6, 9, and 12. main outcome measures: Changes in BCVA, central macular thickness (CMT), and total macular volume (TMV). Results The mean logarithm of the minimal angle of resolution (logMAR) BCVA improved significantly, and mean CMT and TMV were significantly reduced in the IVTA group compared with the laser-only group (controls) at all study follow-up visits ( P < .001). The mean logMAR BCVA (Snellen equivalent) was 0.44 (20/50−2 ) for the IVTA group and 0.38 (20/50+1 ) for the controls at baseline, and 0.12 (20/25−1 ) for the IVTA group and 0.32 (20/40−1 ) for the controls at 12 months ( P < .001). The mean CMT and TMV were, respectively, 360 μm and 8.59 mm 3 for the IVTA group and 331 μm and 8.44 mm 3 for the controls at baseline, and 236 μm and 7.32 mm 3 for the IVTA group and 266 μm and 7.78 mm 3 for the controls at 12 months ( P < .001). Conclusions The combination of laser photocoagulation with IVTA was associated with improved BCVA and decreased CMT and TMV when compared with laser photocoagulation alone for the treatment of moderate PDR with CSME.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/j.ajo.2008.08.024</identifier><identifier>PMID: 18929352</identifier><identifier>CODEN: AJOPAA</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Biological and medical sciences ; Cataracts ; Clinical trials ; Colleges & universities ; Combined Modality Therapy ; Diabetes Mellitus, Type 2 - complications ; Diabetes. Impaired glucose tolerance ; Diabetic retinopathy ; Diabetic Retinopathy - physiopathology ; Diabetic Retinopathy - therapy ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Eye surgery ; Female ; Glucocorticoids - therapeutic use ; Glycated Hemoglobin A - analysis ; Hemorrhage ; Hospitals ; Humans ; Injections ; Laser Coagulation - methods ; Lasers ; Macular degeneration ; Macular Edema - physiopathology ; Macular Edema - therapy ; Male ; Medical sciences ; Middle Aged ; Miscellaneous ; Nitric oxide ; Ophthalmology ; Retina - pathology ; Retinopathies ; Standard deviation ; Tomography, Optical Coherence ; Treatment Outcome ; Triamcinolone Acetonide - therapeutic use ; Visual Acuity - physiology ; Vitreous Body</subject><ispartof>American journal of ophthalmology, 2009-02, Vol.147 (2), p.291-297.e2</ispartof><rights>Elsevier Inc.</rights><rights>2009 Elsevier Inc.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3</citedby><cites>FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21148642$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18929352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maia, Otacilio O</creatorcontrib><creatorcontrib>Takahashi, Beatriz S</creatorcontrib><creatorcontrib>Costa, Rogerio A</creatorcontrib><creatorcontrib>Scott, Ingrid U</creatorcontrib><creatorcontrib>Takahashi, Walter Y</creatorcontrib><title>Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>Purpose To evaluate laser combined with intravitreal triamcinolone acetonide (IVTA) for the management of patients with proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME). Design Randomized clinical trial. Methods settings: Single center. study population: Twenty-two patients with bilateral treatment-naïve moderate PDR and CSME. intervention: Laser (panretinal and macular) photocoagulation was performed in each eye, followed by IVTA in one randomly assigned eye. Best-corrected visual acuity (BCVA), fundus photography, and optical coherence tomography were performed at baseline and at months 1, 3, 6, 9, and 12. main outcome measures: Changes in BCVA, central macular thickness (CMT), and total macular volume (TMV). Results The mean logarithm of the minimal angle of resolution (logMAR) BCVA improved significantly, and mean CMT and TMV were significantly reduced in the IVTA group compared with the laser-only group (controls) at all study follow-up visits ( P < .001). The mean logMAR BCVA (Snellen equivalent) was 0.44 (20/50−2 ) for the IVTA group and 0.38 (20/50+1 ) for the controls at baseline, and 0.12 (20/25−1 ) for the IVTA group and 0.32 (20/40−1 ) for the controls at 12 months ( P < .001). The mean CMT and TMV were, respectively, 360 μm and 8.59 mm 3 for the IVTA group and 331 μm and 8.44 mm 3 for the controls at baseline, and 236 μm and 7.32 mm 3 for the IVTA group and 266 μm and 7.78 mm 3 for the controls at 12 months ( P < .001). Conclusions The combination of laser photocoagulation with IVTA was associated with improved BCVA and decreased CMT and TMV when compared with laser photocoagulation alone for the treatment of moderate PDR with CSME.</description><subject>Biological and medical sciences</subject><subject>Cataracts</subject><subject>Clinical trials</subject><subject>Colleges & universities</subject><subject>Combined Modality Therapy</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic retinopathy</subject><subject>Diabetic Retinopathy - physiopathology</subject><subject>Diabetic Retinopathy - therapy</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Eye surgery</subject><subject>Female</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Hemorrhage</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Injections</subject><subject>Laser Coagulation - methods</subject><subject>Lasers</subject><subject>Macular degeneration</subject><subject>Macular Edema - physiopathology</subject><subject>Macular Edema - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Nitric oxide</subject><subject>Ophthalmology</subject><subject>Retina - pathology</subject><subject>Retinopathies</subject><subject>Standard deviation</subject><subject>Tomography, Optical Coherence</subject><subject>Treatment Outcome</subject><subject>Triamcinolone Acetonide - therapeutic use</subject><subject>Visual Acuity - physiology</subject><subject>Vitreous Body</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp9kt2K1DAUx4so7uzqA3gjAdG7jkmbSRoFQcZVF0ZWxvU6nKanmLFNxqQdmH0RX9fUKS7shXBIcsjvfOT8k2XPGF0yysTr3RJ2fllQWi0nK_iDbMEqqXJWKfYwW1BKi1yVip9l5zHukiskl4-zs3RfqHJVLLLfa9_X1mFDNhAxEHANuXJDgIMdAkJHboKF3ljnO--QtD6Qr8F3tsUAgz0g-WChxsEask2r83sYfhz_ZvkCZuwgkMsGe3hDrh3mR0z-FuPYDZH4lgDZJtL39jbVX3fWWTNX7J5kj1roIj6d94vs-8fLm_XnfHP96Wr9fpMbLviQoyxNY-qylWWhTG2gLmqkrF3Jkjd8Rat0ZqyBVq0kGCbpynCujJJKpEDalhfZq1PeffC_RoyD7m002HXg0I9RC1FxKQVL4It74M6PwaXeNGNlVQnGFU0UO1Em-BgDtnofbA_hqBnVk2Z6p5NmetJMT1bwFPN8zjzWPTZ3EbNICXg5AxDTgNoAztj4jysY45XgE_f2xGEa2MFi0NFYdAYbG9AMuvH2v228uxdtZkV-4hHj3Wt1LDTV36bPNf2tNGMqhCzLP0Z8ylY</recordid><startdate>20090201</startdate><enddate>20090201</enddate><creator>Maia, Otacilio O</creator><creator>Takahashi, Beatriz S</creator><creator>Costa, Rogerio A</creator><creator>Scott, Ingrid U</creator><creator>Takahashi, Walter Y</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20090201</creationdate><title>Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial</title><author>Maia, Otacilio O ; Takahashi, Beatriz S ; Costa, Rogerio A ; Scott, Ingrid U ; Takahashi, Walter Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Biological and medical sciences</topic><topic>Cataracts</topic><topic>Clinical trials</topic><topic>Colleges & universities</topic><topic>Combined Modality Therapy</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic retinopathy</topic><topic>Diabetic Retinopathy - physiopathology</topic><topic>Diabetic Retinopathy - therapy</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Eye surgery</topic><topic>Female</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Hemorrhage</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Injections</topic><topic>Laser Coagulation - methods</topic><topic>Lasers</topic><topic>Macular degeneration</topic><topic>Macular Edema - physiopathology</topic><topic>Macular Edema - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Nitric oxide</topic><topic>Ophthalmology</topic><topic>Retina - pathology</topic><topic>Retinopathies</topic><topic>Standard deviation</topic><topic>Tomography, Optical Coherence</topic><topic>Treatment Outcome</topic><topic>Triamcinolone Acetonide - therapeutic use</topic><topic>Visual Acuity - physiology</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maia, Otacilio O</creatorcontrib><creatorcontrib>Takahashi, Beatriz S</creatorcontrib><creatorcontrib>Costa, Rogerio A</creatorcontrib><creatorcontrib>Scott, Ingrid U</creatorcontrib><creatorcontrib>Takahashi, Walter Y</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maia, Otacilio O</au><au>Takahashi, Beatriz S</au><au>Costa, Rogerio A</au><au>Scott, Ingrid U</au><au>Takahashi, Walter Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>2009-02-01</date><risdate>2009</risdate><volume>147</volume><issue>2</issue><spage>291</spage><epage>297.e2</epage><pages>291-297.e2</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><coden>AJOPAA</coden><abstract>Purpose To evaluate laser combined with intravitreal triamcinolone acetonide (IVTA) for the management of patients with proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME). Design Randomized clinical trial. Methods settings: Single center. study population: Twenty-two patients with bilateral treatment-naïve moderate PDR and CSME. intervention: Laser (panretinal and macular) photocoagulation was performed in each eye, followed by IVTA in one randomly assigned eye. Best-corrected visual acuity (BCVA), fundus photography, and optical coherence tomography were performed at baseline and at months 1, 3, 6, 9, and 12. main outcome measures: Changes in BCVA, central macular thickness (CMT), and total macular volume (TMV). Results The mean logarithm of the minimal angle of resolution (logMAR) BCVA improved significantly, and mean CMT and TMV were significantly reduced in the IVTA group compared with the laser-only group (controls) at all study follow-up visits ( P < .001). The mean logMAR BCVA (Snellen equivalent) was 0.44 (20/50−2 ) for the IVTA group and 0.38 (20/50+1 ) for the controls at baseline, and 0.12 (20/25−1 ) for the IVTA group and 0.32 (20/40−1 ) for the controls at 12 months ( P < .001). The mean CMT and TMV were, respectively, 360 μm and 8.59 mm 3 for the IVTA group and 331 μm and 8.44 mm 3 for the controls at baseline, and 236 μm and 7.32 mm 3 for the IVTA group and 266 μm and 7.78 mm 3 for the controls at 12 months ( P < .001). Conclusions The combination of laser photocoagulation with IVTA was associated with improved BCVA and decreased CMT and TMV when compared with laser photocoagulation alone for the treatment of moderate PDR with CSME.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>18929352</pmid><doi>10.1016/j.ajo.2008.08.024</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9394 |
ispartof | American journal of ophthalmology, 2009-02, Vol.147 (2), p.291-297.e2 |
issn | 0002-9394 1879-1891 |
language | eng |
recordid | cdi_proquest_miscellaneous_66847761 |
source | ScienceDirect Journals |
subjects | Biological and medical sciences Cataracts Clinical trials Colleges & universities Combined Modality Therapy Diabetes Mellitus, Type 2 - complications Diabetes. Impaired glucose tolerance Diabetic retinopathy Diabetic Retinopathy - physiopathology Diabetic Retinopathy - therapy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Eye surgery Female Glucocorticoids - therapeutic use Glycated Hemoglobin A - analysis Hemorrhage Hospitals Humans Injections Laser Coagulation - methods Lasers Macular degeneration Macular Edema - physiopathology Macular Edema - therapy Male Medical sciences Middle Aged Miscellaneous Nitric oxide Ophthalmology Retina - pathology Retinopathies Standard deviation Tomography, Optical Coherence Treatment Outcome Triamcinolone Acetonide - therapeutic use Visual Acuity - physiology Vitreous Body |
title | Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A00%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20Laser%20and%20Intravitreal%20Triamcinolone%20for%20Proliferative%20Diabetic%20Retinopathy%20and%20Macular%20Edema:%20One-year%20Results%20of%20a%20Randomized%20Clinical%20Trial&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Maia,%20Otacilio%20O&rft.date=2009-02-01&rft.volume=147&rft.issue=2&rft.spage=291&rft.epage=297.e2&rft.pages=291-297.e2&rft.issn=0002-9394&rft.eissn=1879-1891&rft.coden=AJOPAA&rft_id=info:doi/10.1016/j.ajo.2008.08.024&rft_dat=%3Cproquest_cross%3E66847761%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1138861490&rft_id=info:pmid/18929352&rfr_iscdi=true |